← Back to Clinical Trials
Recruiting NCT03886584

NCT03886584 Source Monitoring Déficit in Neuropsychiatric Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03886584
Status Recruiting
Phase
Sponsor Hôpital le Vinatier
Condition Psychiatric Disorder
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2019-03-08
Primary Completion 2026-03-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Monitoring source test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2019-03-08 with a primary completion date of 2026-03-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

the investigators will measure source-monitoring ability in patients with several neuropsychiatric condition and in healthy controls appaired in age, sex and educational level. Source-monitoring will be measured thanks to internal- and reality-monitoring informatic tasks.The investigators hypothesized patients with fronto-temporal abnormalities would show more marked deficits than patients with only frontal abnormalities.

Eligibility Criteria

Inclusion Criteria: * Subjects who gave their free and informed consent; * Men and women; * Aged 18 to 80; * Having normal or corrected vision; * Mastering the French language (read and spoken); * All subjects will not have a working memory deficit preventing the test from being passed (MMSE short version):AM patients should have a score of \<MMSE \<26; Patients with pre-dementia AD will be diagnosed according to Dubois criteria (Dubois et al., 2016); patients with early FTD will be diagnosed according to Rascovsky's criteria (Rascovsky et al., 2011); Patients with DCL will be diagnosed according to McKeith's criteria (McKeith et al., 2005), TBP patients will be diagnosed using DSM 5 criteria (Arlington VA, 2013). Exclusion Criteria: * Inadmissibility of the consent or refusal of the subject. * Patients under guardianship

Contact & Investigator

Central Contact

JEROME BRUNELIN, PHD

✉ jerome.brunelin@ch-le-vinatier.fr

📞 00334 37 91 55 65

Principal Investigator

JEROME BRUNELIN, PHD

PRINCIPAL INVESTIGATOR

Centre Hospitalier Le Vinatier - CRNL - INSERM

Frequently Asked Questions

Who can join the NCT03886584 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Psychiatric Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03886584 currently recruiting?

Yes, NCT03886584 is actively recruiting participants. Contact the research team at jerome.brunelin@ch-le-vinatier.fr for enrollment information.

Where is the NCT03886584 trial being conducted?

This trial is being conducted at Bron, France.

Who is sponsoring the NCT03886584 clinical trial?

NCT03886584 is sponsored by Hôpital le Vinatier. The principal investigator is JEROME BRUNELIN, PHD at Centre Hospitalier Le Vinatier - CRNL - INSERM. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology